Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

Verve Therapeutics is looking to submit its opt-in package to partner Eli Lilly after the announcement of positive data from the Phase Ib study of VERVE-102 in heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD), in the hopes of bringing the large pharma company on board with the in vivo gene editing program.

Key Takeaways

Verve announced positive results from the Phase Ib Heart-2 trial of VERVE-102, with competitive cholesterol lowering and clean safety for the gene-editing therapy.

The biotech announced 14 April initial data from 14 patients in the Phase Ib Heart-2 trial of VERVE-102, showing that...